US FDA outreach to the regenerative medicine community: challenges and opportunities
- PMID: 22817631
- DOI: 10.2217/rme.12.36
US FDA outreach to the regenerative medicine community: challenges and opportunities
Abstract
Advances in the field of regenerative medicine have yielded novel approaches to developing treatments for currently unmet medical needs. The regenerative medicine field is diverse, spanning many research and clinical disciplines; no single society or organization fully represents regenerative medicine. The US FDA maintains an active dialog with a variety of stakeholders to keep abreast of the latest available science, to anticipate regulatory challenges posed by the latest scientific developments and to educate stakeholders about regulatory expectations for product development. The diversity of stakeholders in this field makes this dialog challenging. This article provides an overview of some of the FDA's current outreach activities in this area. The FDA welcomes opportunities to enhance its interactions with the regenerative medicine community.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources